Background: With the implementation of multidisciplinary treatment and development of multiple novel anticancer drugs in parallel with expanding knowledge of supportive and palliative care, a need for separate training and specialisation in medical oncology emerged. A Global Curriculum (GC) in medical oncology, developed and updated by a joint European Society for Medical Oncology/American Society of Clinical Oncology (ESMO/ASCO) GC Task Force/Working Group (GC WG), greatly contributed to the recognition of medical oncology worldwide.

Material and methods: ESMO/ASCO GC WG carried out a global survey on medical oncology recognition and GC adoption in 2019.

Results: Based on our survey, medical oncology is recognised as a separate specialty or sub-specialty in 47/62 (75%) countries participating in the survey; with a great majority of them (39/47, 83%) recognising medical oncology as a standalone specialty. Additionally, in 9 of 62 (15%) countries, medical oncology is trained together with haematology as a specialty in haemato-oncology or together with radiotherapy as a specialty in clinical oncology. As many as two-thirds of the responding countries reported that the ESMO/ASCO GC has been either fully or partially adopted or adapted in their curriculum. It has been adopted in a vast majority of countries with established training in medical oncology (28/41; 68%) and adapted in 12 countries with mixed training in haemato-oncology, clinical oncology or other specialty responsible for training on systemic anticancer treatment.

Conclusions: With 75% of participating countries reporting medical oncology as a separate specialty or sub-specialty and as high as 68% of them reporting on GC adoption, the results of our survey on global landscape are reassuring. Despite a lack of data for some regions, this survey represents the most comprehensive and up-to-date information about recognition of medical oncology and GC adoption worldwide and will allow both societies to further improve the dissemination of the GC and global recognition of medical oncology, thus contributing to better cancer care worldwide.

Kew words: medical oncology, medical oncology recognition, Global Curriculum, Global Curriculum adoption

INTRODUCTION

Global care of patients with cancer is constantly improving. Whereas the incidence rates are still rising, the mortality rates for many cancers are declining, with major improvements observed in the survival rates of most cancers including some of the most common cancers, such as breast and colorectal cancer.\(^1,2\) There are three major pillars of cancer therapy, i.e. surgery, radiation therapy and systemic therapy, all of which have contributed substantially to improved cancer control over the last decades. With the implementation of multidisciplinary treatment strategies and team-based cancer care, all these disciplines flourished and gained an important independent place in multidisciplinary cancer care.\(^3\) With the development of multiple novel anticancer drugs and improved understanding of
their mechanisms of action and pharmacology in parallel with ever expanding knowledge of supportive and palliative care, it became obvious that a separate structured training and specialisation in medical oncology is necessary for ensuring safe and efficient anticancer systemic therapy worldwide.4

Medical oncology has been established as a new sub-specialty of internal medicine in the USA, already in 1965.5 Although some European countries were among the pioneers in establishing essential principles in systemic anticancer treatment and medical oncology as an independent specialty, the legislation process of full recognition of medical oncology took a bit longer in the European Union (EU)6 and other parts of the world. Europe has a long history of heterogeneity in medical oncology training in terms of the curriculum and duration of training in medical oncology, as well as recognition of medical oncology as a separate specialty. Some countries still prefer a mixed type of oncology training and specialties like haemat-oncology or clinical oncology. While the political support for the recognition of medical oncology as a separate specialty in line with the European directive on the recognition of professional qualifications (Directive2005/36/EC)6 has been increasing, it became clear that a standardisation of the minimal training period and curriculum in medical oncology is needed.

Development of a Global Curriculum (GC) in Medical Oncology by a joint European Society for Medical Oncology/ American Society of Clinical Oncology (ESMO/ASCO) GC Task Force, which was later extended to a permanent GC Working Group (GC WG), has greatly contributed to the recognition of medical oncology as a separate professional qualification by the EU in March 2011.6,6 The curriculum defined a minimum training period of 5 years, divided into at least 2-3 years of internal medicine and 2-3 years of medical oncology.10-12 The first edition of the ESMO/ASCO GC was originally published simultaneously in the Annals of Oncology and Journal of Clinical Oncology in 2004.10,11 It was updated in 201012 and followed by a completely new edition in 2016.13 Each of those editions introduced updated information and skills that medical oncologists need to know and be trained in, to be able to best implement them in their everyday clinical practice. With a comprehensive and updated list of objectives, knowledge, awareness and skills in a wide field of diagnostics and treatment of solid tumours, as well as haematological malignancies, the ESMO/ASCO GC represents a very useful educational tool to be implemented into national training programmes. It provides a platform that supports the recognition of medical oncology worldwide.

The previous survey on medical oncology recognition and ESMO/ASCO GC adoption was carried out in 2013 at the European level.1 The aim of our current survey carried out at the end of 2018 was to obtain a worldwide picture of medical oncology training and recognition, ESMO/ASCO GC adoption as well as a snapshot of global workforce in medical oncology, which might serve as a tool for internal societies planning.

MATERIALS AND METHODS

The online survey was developed by the ESMO/ASCO GC WG based on the previous edition, with some additional questions incorporated. The survey link was sent to the ESMO national representative, national society or the leader of the training programme in 91 countries with whom either ESMO or ASCO had official relations at the time of survey. Despite repeated requests, 22 countries did not respond at all, whereas 7 countries provided too little data to be included in the analysis, resulting in a final list of 62 participating countries. The survey started online in the last quarter of 2018 and was followed by a series of in-person interviews with the responders in 2019. After >1 year of intensive work on collecting and clarifying the data, we present here the status of global medical oncology recognition and ESMO/ASCO GC adoption in 2019.

Medical oncology recognition

Based on our survey, medical oncology is recognised as a separate specialty or sub-specialty in 47/62 (75%) of participating countries, with a great majority of them (39/ 47, 83%) recognising medical oncology as a specialty (Figure 1). In all but one country, the duration of training in medical oncology fulfills the recommended minimal duration of 5 years.13 Whereas medical oncology has been established as a specialty in the USA, all South American as well as Western and Central-Eastern European countries, it is recognised as a sub-specialty in Canada and the vast majority of Eastern Mediterranean and South-East Asian countries that participated in our survey (Figure 1). In addition, in 9 of 62 (15%) countries, medical oncology is trained together with haematology as a specialty in haemat-oncology or together with radiotherapy as a specialty in clinical oncology (Figure 1). Haematology is recognised as a separate specialty in Austria, Germany and Lebanon. Of note, several months of training in haematology is foreseen within medical oncology specialisation or subspecialisation in most countries. In addition, systemic anticancer treatment is trained in the frame of a separate haematology programme in many countries around the world. However, standalone haematology training should be clearly distinguished from the training model in haematology. In the majority of Nordic countries, clinical oncology is still considered as the most appropriate training model for oncologists providing systemic anticancer therapy, whereas in many big academic centres, clinical oncologists become dedicated early on during their career to either systemic anticancer treatment or radiotherapy. In some countries, like Bangladesh, Croatia, Egypt and Ghana, both medical oncology and clinical oncology are recognised as a standalone specialty. Based on our survey, the remaining 6/62 (10%) countries still do not recognise either medical oncology or haematology or clinical oncology as a separate specialty or sub-specialty. In all those countries, systemic anticancer treatment is trained in the frame of a broad specialisation in oncology. This is specific mostly for countries from the former Soviet Union or close
neighbourhood. Some of those countries reported problems, such as availability of limited resources for transforming the current training model in oncology or prolonging otherwise short oncology training due to logistical and financial issues, but some countries like Kazakhstan reported on work in progress in establishing medical oncology as a separate specialisation.

Some small European countries, i.e. Iceland and Luxembourg, do not provide training in medical oncology, but they do recognise it as a speciality, and medical

---

Figure 1. Recognition of medical oncology.
The map (A) and the list (B) of countries.

* Training abroad.
** Duration shorter than recommended by Global Curriculum.

---

| Medical Oncology recognised as speciality |
|-----------------------------------------|
| Argentina                              |
| Bangladesh                             |
| Belgium                                |
| Bosnia and Herzegovina                 |
| Brazil                                 |
| Bulgaria                               |
| China                                  |
| Croatia                                |
| Cyprus                                 |
| Czech Republic                         |
| Egypt                                  |
| France                                 |
| Ghana*                                 |
| Greece                                 |
| Honduras*                              |
| Hungary                                |
| Iceland*                               |
| India                                  |
| Ireland                                |
| Israel                                 |
| Italy                                  |
| Kenya                                  |
| Latvia                                 |
| Lithuania                              |
| Luxembourg*                            |
| Montenegro*                            |
| Myanmar***                             |
| New Zealand                            |
| Poland                                 |
| Portugal                               |
| Romania                                |
| Serbia                                 |
| Singapore                              |
| Slovak Republic                        |
| Slovenia                               |
| Spain                                  |
| Switzerland                            |
| United States                          |
| of America                             |

| Medical Oncology recognised as sub-speciality |
|-----------------------------------------------|
| Canada                                        |
| Indonesia                                     |
| Japan                                         |
| Panama                                        |
| Philippines                                   |
| Saudi Arabia                                  |
| South Africa                                  |
| Turkey                                        |

| Clinical Oncology |
|-------------------|
| Bangladesh        |
| Croatia           |
| Denmark           |
| Egypt             |
| Estonia           |
| Finland           |
| Ghana             |
| Honduras*         |
| Iceland*          |
| Lebanon           |
| Luxembourg*       |

| Haematology-Oncology |
|----------------------|
| Austria              |
| Germany              |
| Honduras*            |
| Lebanon              |
| Luxembourg*          |

| Medical Oncology NOT recognised |
|---------------------------------|
| Albania                          |
| Armenia                          |
| Belarus                          |
| Kazakhstan                       |
| North Macedonia                  |
| Russian Federation               |

---

*Training abroad
**Duration shorter than recommended by Global Curriculum
oncologists trained abroad are recognised as certified medical oncologists in their countries. The same situation exists in some non-European countries like Ghana and Honduras. Montenegro stated that part of their training programme in medical oncology is taking part abroad in the frame of the training programme in Serbia, while basic training is carried out in the academic centre in Montenegro.

Encouraging enough, there is a widespread recognition of medical oncology around the globe. In a vast majority of countries that participated in our survey, medical oncology is recognised as a specialty or sub-speciality. Actually, all participating countries from the region of America and the majority of the Asian and African countries reported having established training in medical oncology. It has to be noted, however, that only a small number of African countries participated in the survey. When comparing the status of medical oncology recognition in Europe now with earlier reports, there has been no major improvement since 2013. This might be explained partly by the fact that already in 2013, two-thirds of the European countries recognised medical oncology as a separate specialty, and it is not so easy to reach the remaining countries where significant obstacles seem to be present. Obviously in some European regions there is still a belief that a mixed training of medical oncology with haematology or radiation oncology under specialisation in either haemato-oncology or clinical oncology provides optimal education for their specialists providing systemic anticancer therapy. The Euro-Asian region still has important unmet needs in establishing medical oncology as a separate training programme and specialty, and requires our additional support and efforts.

GC adoption

As many as two-thirds of 61 participating countries reported that the ESMO/ASCO GC has been either fully or partially adopted or adapted in their curriculum (Figure 2). Only for one responding country we were not able to retrieve the status of the GC adoption, in particular for Switzerland, which in our previous survey reported that the GC is applicable, but not adopted. For countries recognising medical oncology as a separate specialty or sub-specialty, a full or partial adoption of GC in medical oncology was considered, while for the countries with mixed training in haemato-oncology or clinical oncology, the adoption of their curriculum in systemic anticancer treatment on the basis of the GC has been reported.

In most countries with medical oncology recognised and trained as a specialty or sub-specialty (28/41; 68%), the ESMO/ASCO GC has been adopted into training programmes. In the majority of countries, the GC has been adopted partially, due to a predominant approach of responding countries to stick to their national curriculum. As stated during the interviews, such a policy allows them to better tailor the curriculum to local needs and resources. The existence of the national curriculum was reported for as many as 42/62 (68%) countries participating in the survey. In most countries, the latest version of the GC from 2016 has been adopted, which is good in the light of rapidly evolving knowledge in medical oncology. For some countries, like Italy, it was reported that the GC has been adopted in some training centres, but not in the whole country. Despite the fact that about one-third of countries with recognised medical oncology as a specialty or sub-specialty still did not adopt the GC formally, it is reassuring that almost all respondents commented that the GC could be applicable in their countries, at least partly. There are some countries with large populations among them, such as Canada and China. Only a few of them expressed some concerns related to the country language issues, complexity of the GC, as well as administrative barriers. For some countries, like France, it was reported that they are in the process of adapting their training according to the GC.

The ESMO/ASCO GC has been adapted into the curriculum of mixed training in haemato-oncology in all three countries where haemato-oncology is recognised as a specialty (i.e. Austria, Germany and Lebanon). Both Austria and Germany achieved the GC adaptation between the time of our earlier survey in 2013 and 2018. In countries with clinical oncology or any other specialty responsible for training on systemic anticancer treatment, however, the rate of incorporation and adoption of GC into their curricula is lower. Only one out of six countries (i.e. Sweden) with clinical oncology as a recognised training for systemic anticancer therapy reported on adoption of GC into their curriculum.

Notably, the ESMO/ASCO GC has been either adopted or adapted in multiple countries across all continents. There are no major differences in GC adoption between the world regions (Figure 2). Self-evidently, the GC adoption is seen only in the countries and regions with medical oncology recognition, whereas in the other regions GC has been adopted. It is reassuring that even in the low- and middle-income countries with limited resources, such as Kenya and South Africa, the GC has been adopted; with respondents from these countries reporting about no major challenges in adopting our GC. When comparing the status of GC adoption/adoption in Europe in the current global survey with the status reported in 2013, improvement is seen in Central and Southern Europe with Austria, Germany and Spain having adopted/adapted the GC since the previous European survey. But there are still regions in all continents in which awareness about the GC still needs to be spread out.

DISCUSSION

Based on our global survey, medical oncology is currently recognised as a specialty or sub-specialty in all continents and at least in 47 countries all around the world. The ESMO/ASCO GC which played a pivotal role in setting up the medical oncology training has been adopted in a substantial majority of medical oncology training programmes worldwide. It has also been incorporated into mixed training programmes for haemato-oncology and clinical oncology.
With 75% of participating countries reporting medical oncology as a separate specialty or sub-specialty and as high as 68% of them reporting on GC adoption, the results of our current survey on global landscape are comparable to the European landscape in 2013, which is reassuring; especially since the current global survey included many more countries with limited resources and less developed systems of education and specialisations.

More concretely, the results of our previous European survey revealed that two-thirds of European countries...
recognised medical oncology as a distinct specialty or sub-specialty and that the ESMO/ASCO GC has been adopted or adapted in 14/46 participating countries. It is encouraging that the overspread of countries that recognise medical oncology as a standalone specialty or sub-specialty in our global survey is almost at the same level, not just in American, but also in South-East Asia and Western Pacific regions. In addition, the current survey carried out at the global level found even higher rates of GC adoption, which shows that despite being breadth and complex, the ESMO/ASCO GC remains highly applicable at the global level. We believe that a major contributing factor for such a situation is that it has always been updated based on suggestions from colleagues working on medical oncology training programmes worldwide. Many of them contributed as co-authors or editorial board members of updated ESMO/ASCO GC versions. In this way, not only have novel therapeutic approaches been introduced, but also elementary chapters, such as supportive and palliative care, have been constantly updated. Additionally, it should be considered that the global survey was carried out 5 years after the European one, thus giving countries more time for the GC adoption.

Despite the in-depth work on collecting global data, followed by >1 year of intensive efforts to clarify the data through multiple in-person interviews and communications, our results are subject to several limitations. When looking into data, it should be considered that due to the long-lasting above-mentioned efforts, the landscape status might have changed even before being published. From our interviews with the survey respondents, however, we have learned that changes at the national level are rather a subject of lengthier legislative procedures. As in any survey, the responders may not be representative of all providers in the system and in some larger countries, of all regions. The information provided by the respondents was also not checked by the national authorities, although they have been contacted for participation in this survey by a representative entity in their respective countries. Our survey results are further limited by the lack of responses from some countries. For example, we are missing responses from some large countries, such as Australia. Of note, our WG had very fruitful previous collaborations and discussions with Australian colleagues about GC implementation, thus being aware of all their efforts and activities related to the recognition of medical oncology and implementation of a high-level training programme in their country. The GC WG even modelled the first ESMO/ASCO Global Core Curriculum for Training in Medical Oncology Log Book based on Australian experience. We emphasise the importance of monitoring the implementation of the GC by recommending the use of the ESMO/ASCO Global Curriculum Log Book, which is considered as a supplement for recording the various aspects and parts of the medical oncology training programme. In addition, low-income countries have the lowest number of responders in our survey, indicating difficulties in reaching medical oncologists in these countries. There is a lack of data on education and training in oncology for most of the African countries. Due to a continuous increasing burden of cancer in those countries, we will continue our efforts for closer collaboration with medical doctors and health authorities in the region and offer them support in establishing medical oncology training programmes tailored to their needs and resources, but still in line with global recommendations.

Conclusions

These data represents the most comprehensive and up-to-date information about recognition of medical oncology and adoption of the ESMO/ASCO GC worldwide. They provide an excellent platform for our further and more expanded activities on global medical oncology recognition. By conducting multiple interviews, a good connection with local societies and leaders in medical oncology has been established which will certainly boost our common activities in the future. We also received valuable suggestions on how to prepare the updated version of the ESMO/ASCO GC to maximise its global applicability and adoption. The important data and experiences gained by conducting this global survey will allow ESMO and ASCO as leading oncology societies to further improve dissemination of the GC and global recognition of medical oncology, thus contributing to better care of cancer patients worldwide.

ACKNOWLEDGEMENTS

We thank the following country respondents (all stated functions refer to time of response collection): Albania—Enkelejda Cuedari, ESMO National Representative of Albania selected by the Albanian Oncology Association, The Oncology Service, Mother Theresa Hospital in Tirana; Argentina—Gustavo Lopez, a member of the Steering Committee (Comisión Directiva) of the Asociación Argentina de Oncología Clínica (AAOC), Head of Oncology and Palliative Care in the Hospital Bernardo Houssay in Vicente López, an ESMO Designated Centre; Armenia—Davit Zohrabyan, Head of Solid Tumour Treatment Department, Chemotherapy Clinic, Muratsan Hospital Complex, Yerevan State Medical University in Yerevan; Austria—Wolfgang Eisterer, ESMO National Representative of Austria selected by the Austrian Society for Hematology and Medical Oncology; Bangladesh—Mollah Obayedullah Baki, President of Bangladesh Cancer Society, Obayedullah-Ferdousi Foundation Cancer Hospital and Research Institute, Executive Member of Bangladesh Society of Radiation Oncologists, former Director and Professor of Radiation Oncology at National Institute of Cancer Research and Hospital, former Executive Member of Bangladesh Medical and Dental Council; Belarus—Sergei Krasny, ESMO National Representative-Elect of Belarus, Deputy Director for Research, N.N. Alexandrov National Cancer Centre of Belarus, and Yauheni Baranau, ESMO National Representative of Belarus, Head of Chemotherapy Department, Minsk City Clinical Oncological Dispensary; Belgium—Peter Vuylsteke, ESMO National Representative of Belgium; Bosnia and Herzegovina—Timur Ceric, Head of Outpatient Unit,
Clinic of Oncology, Clinical Centre Sarajevo University, Associate Professor of Oncology at Medical Faculty of Sarajevo, a member of Board of Directors of Society of Oncologists in Bosnia and Herzegovina; Brazil—Gilberto de Castro Junior, ESMO National Representative of Brazil; Bulgaria—Jeliazko Arpadjiev, ESMO National Representative, Head of Medical Oncology Department, Acibadem City Clinic Tokuda Hospital in Sofia; Canada—Sharlene Gill, Secretary/Treasurer of the Canadian Association of Medical Oncologists; China—Yi-Long Wu, Past President of the Chinese Society of Clinical Oncology (CSCO), Tenured Professor of Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences; Croatia—Borislav Belev, Head of Department of Medical Oncology, Clinical Hospital Center Zagreb; Cyprus—George Orphanos, ESMO National Representative of Cyprus; Czech Republic—Tomás Svoboda, ESMO National Representative of Czech Republic, committee member of the Czech Society for Oncology, Head of Radiation Oncology Department, University Hospital Pilsen; Egypt—Rabab Gaafar, Professor of Medical Oncology, National Cancer Institute, Cairo University; Estonia—Anneli Elme, ESMO National Representative of Estonia selected by the Estonian Society for Medical Oncology—EOÜ, Chairman of the Board of Estonian Society for Medical Oncology, member of the Board of Estonian Oncologist Association; Finland—Peeter Karihtala, ESMO National Representative of Finland, Associate Professor, Specialist in Oncology and Radiotherapy; France—Michel Ducreux, ESMO National Representative of France, Medical Affairs Director, Head of GI Oncology Unit, Department of Medical Oncology, Gustave Roussy Cancer Campus in Paris; Ghana—Verna Vanderpuye, trainer and mentor at National Center for Radiotherapy and Nuclear Medicine, Korle-Bu Teaching Hospital in Accra; Greece—Ioannis Boukouvanis, ESMO National Representative of Greece; Honduras—José Angel Sánchez, Haematology Oncology Subspecialist, Professor at the Medical Sciences Faculty of the Universidad Nacional Autónoma de Honduras (UNAH), ASCO member in charge of the project to start training in Medical Oncology-Haematology by the UNAH; Iceland—Asgerdur Sverrisdottir, Specialist in Clinical Oncology, Landspitali University Hospital in Reykjavik; India—Govind Babou, ESMO National Representative of India, HOD — Medical Oncology, Kidwai Memorial Institute of Oncology in Bangalore; Indonesia—Cosphiadi Irawan, ESMO National Representative of Indonesia selected by the Indonesian Society of Hematology Medical Oncology (ISHMO); Ireland—Anne Horgan, ESMO National Representative of Indonesia selected by the Irish Society of Medical Oncology (ISMO); Israel—Wilmos Mermershtain, ESMO National Representative of Israel, Chairman of Israeli Society of Clinical Oncology & Radiation Therapy (ISCORT) and Gil Bar-Sela, Secretary of the ISCORT; Italy—Giuseppe Curigliano, Associate Professor of Medical Oncology at University of Milano; Kazakhstan—Dilyara Kaidarova, Director of the Kazahks Institute of Oncology and Radiology (KazIOR), Head of Oncology Department of Kazakh State Medical University and Zaure Dushimova, Deputy Director of KazIOR, teaching assistant at Oncology Department of Kazakh State Medical University; Kenya—Nicolas Abinya, designer of most oncology training programmes in Kenya, founder member of the Kenyan Society of Hematology and Oncology; Lebanon—Nagi El Saghir and Arafat Tafayli, members of the ESMO/ASCO Global Curriculum Working Group; Lithuania—Sigita Liutkauskiene, mentor in medical oncology, one of the authors of the last trainee programmes in medical oncology at Lithuanian University in Health Sciences, Head of Conservative Oncology Department at Lithuanian University of Health Sciences Kaunas Oncology Hospital, Associate Professor in Lithuanian University of Health Sciences Oncology Institute; Malaysia—Matin Melior Abdullah, President of the Malaysian Oncological Society; Mexico—Samuel Rivera, former President of the National Society of Oncology, Head and Professor of the Department of Medical Oncology UMAE Hospital de Oncologia Centro Médico Nacional XXI, member of the Board of the Colegio Mexicano de Oncología Médica, former Director of the Certification Examination in Medical Oncology in the Consejo Mexicano de Oncología; Montenegro—Vladimir Todorovic, Professor, Director of Oncology and Radiotherapy Clinic in Podgorica; Myanmar—See Aung, President of the Myanmar Oncology Society, Special Advisor to the Minister on Oncology, Professor Emeritus (Medical Oncology), University of Medicine, Visiting Professor (Oncology), Defence Services Medical Academy Professor/Head (Medical Oncology) (Retd.), Chairman, Board of Study (MMedSc Medical Oncology) (Retd.), General Secretary, National Cancer Control Steering Committee; Panama—Roberto Ivan Lopez, former Director of the National Oncology Institute; Philippines—Mary Claire Vega-Soliman, President of the Philippine Society of Medical Oncology (PSMO), Angelie Yeo, Training Committee Member, St. Luke’s Medical Center, Jade Lotus Peneyra, Past President of PSMO, Christin Galvez, Phinnie specialty board for medical oncology examiner; Portugal—Paulo Cortes, ESMO National Representative of Portugal, President of Sociedade Portuguesa de Oncologia, Director of the Oncology Department, Hospital Lusiadas Lisboa in Lisbon; Russian Federation—Alexey Tryakin, ESMO National Representative of Russian Federation, Assistant Professor in academic centre; Saudi Arabia—Abdul Rahman Jazieh, The National Guards Hospital, Past Chair and member of the ASCO International Affairs Committee; Serbia—Davorin Radosavljevic, Visiting Professor of Medical Oncology at the School of Medicine, University of Belgrade, Head of Medical Oncology Clinic at the Institute for Oncology and Radiology of Serbia and Ivana Bozovic-Spasojevic, mentor, Head of the Daily Chemotherapy Hospital at the Institute for Oncology and Radiology of Serbia, both are members of the Oncology Advisory Board in Ministry of Health; Singapore—Ravindran Kanesvaran, President of the Singapore Society of Oncology; Slovak Republic—Michal Mego, Professor and Director of training for medical oncology in the Medical School of Comenius University; Slovenia—Erika Matos, national coordinator for the specialisation in medical oncology; South Africa—Paul Ruff, Chair of the South African Society of...
Medical Oncology, Certificate in Medical Oncology Examination Convener and Examiner, Head of Department of Medical Oncology, University of Witwatersrand, Faculty of Health Sciences, Vice-Chair and Medical Oncology Representative in Ministerial Advisory Committee on Cancer Control and Prevention; Spain—Ramon Colomer, ESMO National Representative of Spain; Switzerland—Christoph Renner, ESMO National Representative of Switzerland selected by the Swiss Society of Medical Oncology (SSMO); Turkey—Pinar Saip, ESMO National Representative of Turkey, President of Turkish Medical Oncology Society (TSMO); United States of America—Michael Kosty, member of ESMO/ASCO Global Curriculum Working Group and Doug Pyle, VP International Affairs, ASCO; Zambia—Dorothy C Lombe, a clinical and radiation oncologist at the Cancer Diseases Hospital in Lusaka. We would also like to thank the ESMO National Representatives (2017-2018) of Denmark, Germany, Hungary, Japan, Latvia, Luxembourg, North Macedonia, New Zealand, Poland, Romania and Sweden for providing data for their respective countries.

We would like to thank Christian Dittrich, Past Chair of the ESMO/ASCO Global Curriculum Working Group for landscape conception and help in data interpretation, ESMO staff Roberta Candiani for help in data collection, Mariya Lemosle for help in data management/analysis and Roberta Ferrandino for project assistance. We sincerely thank the ESMO and ASCO leadership for their support in our Working Group activities.

FUNDING

This work was supported by the European Society for Medical Oncology (ESMO) (no grant number) and the American Society of Clinical Oncology (ASCO) (no grant number) who were the legal sponsors of this project. No research funding for the survey conduct, meetings, data analysis or manuscript preparation was received from any third parties.

DISCLOSURE

TC reports receipt of honoraria for participation in Advisory Board of Boehringer Ingelheim, Takeda, receipt of honoraria as invited speaker from MSD, Pfizer, Roche, institutional financial support for research from Merck Sharp & Dohme (MSD); MK reports receipt of honoraria for consulting or advisory role from Biocent, participating in speakers’ bureau of Astellas Pharma, Genentech, Roche, Sanofi, Lilly, Bayer, Medivation, Astellas, Novartis, Bristol-Myers Squibb (BMS), Janssen Oncology, Pfizer, MSD, institutional research funding from Genentech, Roche, Merck Serono, covered travel and accommodations expenses by Genentech, Bayer, Medivation, Astellas, Sanofi, Novartis, BMS, Janssen Oncology, Pfizer, MSD; PO reports receipt of grants and personal fees from Roche, Merck, Sanofi Oncology, Amgen, Bayer, Eli Lilly, Nordic Drugs, and personal fees from Baxalta/Shire; AA reports receipt of honoraria for participation in Advisory Board of Roche, Pfizer, Eli Lilly and Company, Eisai, Novartis, MSD and BMS; NE-S reports receipt of honoraria from Roche, Novartis, MSD Oncology, AstraZeneca, Lilly, Pfizer, research funding (to Institution) from GlaxoSmithKline, Roche, Novartis; FL reports receipt of honoraria for participation in Advisory Board from Amgen, Astellas, Bayer, Biogen, BMS, Eli Lilly, MSD, Roche, Zymeworks, receipt of honoraria as invited speaker from AstraZeneca, BMS, Eli Lilly, Imedex, Medscape, MedUpdate, MerckSerono, MSD, Promedicis, Roche, Servier, StreamedUp!, receipt of honoraria for expert testimony from Bioinf, Elsevier, receipt of honoraria for writing engagement from Deutscher Ärzteverlag, Iomedico, Springer-Nature, receipt of institutional research grant from BMS; PR reports receipt of honoraria for participation in Advisory Board of Blueprint Medicines, BMS, Merck, MSD, Pierre Fabre, Sanofi, receipt of honoraria as invited speaker from BMS, Merck, MSD, Novartis, Pierre Fabre, Sanofi, institutional research grants from BMS, Pfizer; AT reports receipt of honoraria for participation in Advisory Board from Merck, receipt of honoraria as invited speaker from AstraZeneca, Eli Lilly, Merck, Pfizer; HW reports receipt of honoraria to institution for participation in Advisory Board of AstraZeneca, Biocartis, Daiichi Sanyko, Eisai, KCE, Lilly, Novartis, Orion Corporation, Pfizer, PSI Cro AG, Puma Biotechnology, Roche, Sirtex, institutional research grants from Novartis, Roche, covered travel and accommodations expenses by Pfizer, Roche. All other authors have declared no conflicts of interest.

REFERENCES

1. Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023-1075.
2. Sung H, Ferlay J, Siegal RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
3. El Saghir NS, Charara RN, Kreidieh FY, et al. Global practice and efficiency of multidisciplinary tumor boards: results of an American Society of Clinical Oncology International Survey. J Glob Oncol. 2015;1(2):57-64.
4. Popescu RA, Schäfer R, Caliano R, et al. The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol. 2014;25(1):9-15.
5. Kennedy BJ, Calabresi P, Carbone PP, et al. Training program in medical oncology. Ann Intern Med. 1973;78(1):127-130.
6. Casali PG. Medical oncology: the long-awaited prize of recognition. Ann Oncol. 2011;22(8):1695-1697.
7. Pavlidis N, Alba E, Berardi R, et al. The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe. ESMO Open. 2016;1(1):e000004.
8. The European Parliament and the Council of the European Union. Directive 2005/ 36/EC of the European Parliament and of the Council of 7 September 2005 on the recognition of professional qualifications (text with EEA relevance). OJEU. 2005;L255:22-142.
9. Dittrich C, Kosty M, Jezdik S, et al. ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016. Ann Oncol. 2016;27(8):1378-1381.
10. Hansen HH, Bajorin DF, Muss HB, Purkalne G, Schrijvers D, Stahel R, ESMO/ASCO Task Force on Global Curriculum in Medical Oncology.
11. Hansen HH, Bajorin DF, Muss HB, Purkalne G, Schrijvers D, Stahel R, ESMO/ASCO Task Force on Global Curriculum in Medical Oncology. Recommendations for a Global Core Curriculum in Medical Oncology. J Clin Oncol. 2004;22:4616-4625.

12. ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology: 2010 Update. Available at https://www.esmo.org/content/download/316282/6412696/1/ESMO-ASCO-Revised-Recommendations-for-a-Global-Curriculum-in-Medical-Oncology-2010.pdf. Accessed March 22, 2021.

13. Dittrich C, Kosty M, Jezdic S, et al. ESMO/ASCO Recommendations for a Global Core Curriculum in Medical Oncology Edition 2016. ESMO Open. 2016;1(5):e000097.

14. ESMO/ASCO Recommendations for a Global Core Curriculum in Medical Oncology: 2010 Update. Available at https://www.esmo.org/content/download/105219/1848546/1/The-ESMO-ASCO-Global-Core-Curriculum-for-Training-in-Medical-Oncology-Log-Book-2016.pdf. Accessed March 22, 2021.

15. ESMO/ASCO Global Curriculum Log Book Update 2016. Available at https://www.esmo.org/content/download/81967/1487517/file/The-ESMO-ASCO-Global-Curriculum-for-Training-in-Medical-Oncology-Log-Book-2016.pdf. Accessed March 22, 2021.